Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy & D...
08 December 2020 - 11:01PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced the
appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New
Product Strategy and Development. Dr. Kieffer brings over 20 years
of virologic research and pharmaceutical industry experience to
Enanta, with proven expertise in drug discovery and development,
program management and business development, including having
played significant roles in developing and launching medicines for
infectious and rare diseases.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201208005288/en/
Tara L. Kieffer, Ph.D. (Photo: Business
Wire)
“Tara is joining Enanta at a pivotal time as the company is
advancing its wholly owned pipeline of virology and liver disease
treatments,” stated Jay R. Luly, Ph.D., President and Chief
Executive Officer. “In 2021 and beyond, we anticipate having
multiple data readouts across our pipeline and are eager to
leverage Tara’s scientific expertise in infectious diseases,
combined with her experience in business and product development,
to maximize the opportunities. We welcome her to the company, and
to the senior management team, where we look forward to her
contributions to advance our programs.”
“I am truly impressed with Enanta’s commitment to becoming a
leader in creating small molecule drugs for the treatment of viral
and liver diseases by building on years of antiviral drug discovery
and development expertise and prior successes helping to discover
two marketed products for the treatment of chronic Hepatitis C
infection,” stated Dr. Kieffer. “Enanta has a robust and growing
internal portfolio and I am excited to collaborate with the
experienced team to accelerate the company’s growth to bring
meaningful new treatments to patients.”
Dr. Kieffer joins Enanta from Vertex Pharmaceuticals where she
held roles of increasing responsibility. Most recently, she was
Vice President, External Innovation, Business Development where she
was responsible for assessing the external innovation landscape and
leading projects aimed at identifying in-licensing and acquisition
opportunities. Prior to that, she was Vice President, Integrated
Program Management where she oversaw Vertex's internal development
pipeline and marketed products. Previously, she was Senior
Director, Chief of Staff to the Chief Medical Officer, supporting
strategy and operations across Global Medicines Development and
Affairs. Earlier in her career, Dr. Kieffer was Director, Clinical
Biomarkers within the Translational and Medical Sciences
Department. Prior to that role, she was Head of Clinical Virology,
where she built and led a team responsible for laboratory and
clinical research studies to understand the development of
antiviral drug resistance to Hepatitis C and influenza viruses.
Before joining Vertex, Dr. Kieffer was at Johns Hopkins
University School of Medicine in the Department of Molecular
Biology and Genetics, where her research studies focused on ongoing
replication in patients with well-suppressed Human Immunodeficiency
Virus infection.
Dr. Kieffer graduated summa cum laude from Colgate University
with a B.A. in Molecular Biology. She holds a Ph.D. in Immunology
from Johns Hopkins University School of Medicine. She is co-author
on more than 50 publications and an inventor on multiple patents
involving treatments for Hepatitis C.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates for the following disease
targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV)
and non-alcoholic steatohepatitis (NASH). Enanta is also conducting
research in human metapneumovirus (hMPV) and SARS-CoV-2
(COVID-19).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements,
including statements with respect to the prospects for advancement
of Enanta’s clinical development programs. Statements that are not
historical facts are based on management’s current expectations,
estimates, forecasts and projections about Enanta’s business and
the industry in which it operates and management’s beliefs and
assumptions. The statements contained in this release are not
guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements. Important
factors and risks that may affect actual results include: the
discovery and development risks of Enanta’s programs in RSV, NASH,
HBV, hMPV and SARS-CoV-2; the competitive impact of development,
regulatory and marketing efforts of others in those disease areas;
any continuing impact of the COVID-19 pandemic on Enanta’s business
operations and clinical trials; Enanta’s lack of clinical
development experience; Enanta’s need to attract and retain senior
management and key research and development personnel; Enanta’s
need to obtain and maintain patent protection for its product
candidates and avoid potential infringement of the intellectual
property rights of others; and other risk factors described or
referred to in “Risk Factors” in Enanta’s most recent Form 10-K for
the fiscal year ended September 30, 2020, and other periodic
reports filed more recently with the Securities and Exchange
Commission. Enanta cautions investors not to place undue reliance
on the forward-looking statements contained in this release. These
statements speak only as of the date of this release, and Enanta
undertakes no obligation to update or revise these statements,
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201208005288/en/
Investor and Media Contact: Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024